278 related articles for article (PubMed ID: 18226465)
1. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Duenas-Gonzalez A; Candelaria M; Perez-Plascencia C; Perez-Cardenas E; de la Cruz-Hernandez E; Herrera LA
Cancer Treat Rev; 2008 May; 34(3):206-22. PubMed ID: 18226465
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
3. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.
Blaheta RA; Michaelis M; Driever PH; Cinatl J
Med Res Rev; 2005 Jul; 25(4):383-97. PubMed ID: 15637697
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
6. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic tools in potential anticancer therapy.
Sebova K; Fridrichova I
Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
10. Emerging molecular therapies of advanced thyroid cancer.
Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
Mol Aspects Med; 2010 Apr; 31(2):215-26. PubMed ID: 20176050
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Travaglini L; Vian L; Billi M; Grignani F; Nervi C
Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
14. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Hoffmann K; Czapp M; Löscher W
Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions.
Fukuchi M; Nii T; Ishimaru N; Minamino A; Hara D; Takasaki I; Tabuchi A; Tsuda M
Neurosci Res; 2009 Sep; 65(1):35-43. PubMed ID: 19463867
[TBL] [Abstract][Full Text] [Related]
16. [Development of HDAC inhibitors].
Sowa Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
[TBL] [Abstract][Full Text] [Related]
17. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
18. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic gene regulation in cancer.
Ballestar E; Esteller M
Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the epigenetic code of cancer for therapy.
Smith LT; Otterson GA; Plass C
Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
